Last updated: February 22, 2026
What is NDC 12496-1208?
NDC 12496-1208 corresponds to Fostemsavir (brand name: Rukobia), developed by ViiV Healthcare. It is an antiretroviral medication approved by the FDA in July 2020 for treatment-experienced adults with multidrug-resistant HIV-1 infection.
Market Overview
Current Market Landscape
- Target Population: Approximately 37,000 HIV-positive individuals in the U.S. with multidrug resistance.
- Competitors: Other salvage therapies include ibalizumab (Trogarzo), maraviroc, and enfuvirtide. Fostemsavir's unique mechanism as an attachment inhibitor offers a distinct niche.
- Market Size (2023): Estimated at around $200 million, driven by limited competition and complex patient needs.
Adoption Factors
- Treatment Population: Limited to patients with resistant HIV strains not responding to standard therapies.
- Prescriber Profile: Specialized infectious disease clinics and HIV specialists.
- Dispensing Channels: Specialty pharmacies and hospital formularies.
Regulatory and Reimbursement Environment
- FDA Approval: July 2020.
- Pricing in the U.S.: Approximate wholesale acquisition cost (WAC) at $102,000 per year.
- Insurance Coverage: Limited prior authorization requirements; out-of-pocket costs significant without assistance programs.
Price Projections (2024-2028)
2024 Outlook
- Pricing Stability: The current WAC pricing of ~$102,000 is likely to sustain through 2024 with minimal adjustment.
- Market Penetration: Expected to grow from low-single digits to approximately 8-12% of the salvage HIV market, translating to $16-24 million in revenue.
2025-2028 Projections
| Year |
Estimated Market Share |
Revenue (USD million) |
Notes |
| 2025 |
12-15% |
$24-30 |
Expansion driven by increased awareness and formulary inclusion. |
| 2026 |
15-20% |
$30-40 |
Longer-term adoption among resistant HIV populations. |
| 2027 |
20-25% |
$40-50 |
Growing role as part of combination salvage regimens. |
| 2028 |
25-30% |
$50-60 |
Price stabilization expected; volume increases. |
Influencing Factors
- Pricing Sensitivity: Pricing is high relative to competitors but justified by the drug’s niche.
- Market Uptake: Driven by clinical guidelines, prescribing patterns, and payer coverage.
- Generics & Biosimilars: Not applicable; no generic versions anticipated before 2030 due to patent protections.
Competitive Analysis
| Drug |
Mechanism |
Indications |
Year of Approval |
Price |
Notes |
| Ibalizumab |
Post-attachment inhibitor |
Multidrug-resistant HIV |
2018 |
$30,000 per infusion |
Limited to IV, high cost, less convenient. |
| Maraviroc |
CCR5 antagonist |
HIV-1 |
2007 |
Around $37,000 annually |
Generic versions available but with usage restrictions. |
| Enfuvirtide |
Fusion inhibitor |
HIV-1 |
2003 |
Approx. $20,000 annually |
Requires injections, less favored. |
| Fostemsavir |
Attachment inhibitor |
HIV-1 resistant cases |
2020 |
~$102,000 annually |
First oral attachment inhibitor, high price reflects niche. |
Strategic Insights
- Pricing Power: The niche status affords ViiV Healthcare some pricing leverage, but market share is capped without broader indications.
- Market Access: High-cost treatment may face barriers despite clinical necessary use; patient assistance programs are critical.
- Growth Potential: Limited; constrained by the rare nature of the target population and competition from newer agents.
Key Takeaways
- NDC 12496-1208 (Fostemsavir) is a niche, high-priced drug for resistant HIV-1.
- Market size remains capped at about $200 million globally with steady but slow growth.
- Price stability is expected through 2024, with revenues projected between $16 million and $24 million.
- Future revenue growth depends on increased adoption, payer coverage, and potential label expansions.
- Competitive landscape remains limited but is dominated by other salvage therapies with different administration routes and costs.
FAQs
1. How does Fostemsavir compare price-wise with other HIV drugs?
Fostemsavir’s annual cost of ~$102,000 exceeds older agents like enfuvirtide (~$20,000) and maraviroc (~$37,000), reflecting its niche status and complex patient needs.
2. Are there any biosimilar or generic versions planned?
No. Patent protections extend into the early 2030s, preventing generics or biosimilars from entering the market soon.
3. What factors could impact Fostemsavir’s future pricing?
Market penetration rates, payor negotiations, clinical guideline updates, and new therapy approvals could influence pricing strategies.
4. What is the primary driver of revenue growth?
Increased uptake among treatment-resistant HIV patients and broader insurance coverage.
5. Will new competitors emerge?
Emerging therapies or next-generation attachment inhibitors may challenge Fostemsavir’s niche, but none are approved yet.
References
[1] ViiV Healthcare. (2020). FDA approves Fostemsavir for multi-drug resistant HIV-1 infection.
[2] IQVIA. (2023). U.S. HIV Market Data.
[3] Medicare & Medicaid Services. (2022). Drug pricing and reimbursement policies.
[4] Statista. (2023). Global HIV treatment market forecast.
